XERIS BIOPHARMA HOLDINGS, INC. (XERS) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
XERIS BIOPHARMA HOLDINGS, INC. (XERS) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$189.57 MLiabilities$421.64 MNon-current liabilities$232.07 MCurrent assets$274.76 MAssets$411.91 MNon-current assets$137.15 MEquity−$9.73 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSCash and cash equivalentsInventory, netTrade accounts receivable, netPrepaid expenses and other current assetsOther assetsGoodwillOperating lease right-of-use assetsOther assetsProperty and equipment, netCurrent portion of long-term debtAccrued trade discounts and rebatesOther accrued liabilitiesAccrued returns reserveAccounts payableCurrent operating lease liabilitiesOther current liabilitiesDebt, net of unamortized debt issuance costs, non-current portionNon-current operating lease liabilitiesOther liabilitiesAdditional paid in capitalCommon stock—par value $0.0001, 350,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 173,591,637 and 166,215,410 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyAccumulated deficitAccumulated other comprehensive lossCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityCurrent portion of long-term debtCurrent portion of long-term debt$63.78 MCurrent liabilitiesCurrent liabilities$189.57 MAccrued trade discounts and rebatesAccrued trade discounts and rebates$46.86 MOther accrued liabilitiesOther accrued liabilities$39.71 MLiabilitiesLiabilities$421.64 MAccrued returns reserveAccrued returns reserve$18.60 MAccounts payableAccounts payable$9.34 MCurrent operating lease liabilitiesCurrent operating lease liabilities$6.31 MOther current liabilitiesOther current liabilities$4.98 MNon-current liabilitiesNon-current liabilities$232.07 MDebt, net of unamortized debt issuance costs, non-current portionDebt, net, non-current portion$188.81 MNon-current operating lease liabilitiesNon-current operating lease liabilities$30.54 MOther liabilitiesOther liabilities$12.72 MCurrent assetsCurrent assets$274.76 MCash and cash equivalentsCash and cash equivalents$121.75 MAssetsAssets$411.91 MInventory, netInventory, net$80.93 MTrade accounts receivable, netTrade accounts receivable, net$58.11 MPrepaid expenses and other current assetsPrepaid expenses and other current assets$13.98 MAdditional paid in capitalAdditional paid in capital$690.43 MOther assetsOther assets$82.66 MNon-current assetsNon-current assets$137.15 MGoodwillGoodwill$22.86 MOperating lease right-of-use assetsOperating lease right-of-use assets$21.77 MOther assetsOther assets$5.03 MProperty and equipment, netProperty and equipment, net$4.83 MEquityEquity−$9.73 MCommon stock—par value $0.0001, 350,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 173,591,637 and 166,215,410 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCommon stock—par value $0.0001$18.00 KAccumulated deficitAccumulated deficit−$700.17 MAccumulated other comprehensive lossAccumulated other comprehensive loss−$10.00 K
Chart details

XERIS BIOPHARMA HOLDINGS, INC. (XERS) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
411,905,000 US dollars
Current assets
274,757,000 US dollars
Non-current assets
137,148,000 US dollars
Liabilities
421,639,000 US dollars
Current liabilities
189,568,000 US dollars
Non-current liabilities
232,071,000 US dollars
Equity
negative 9,734,000 US dollars
Cash and cash equivalents
121,747,000 US dollars
Inventory, net
80,930,000 US dollars
Trade accounts receivable, net
58,105,000 US dollars
Prepaid expenses and other current assets
13,975,000 US dollars
Other assets
82,657,000 US dollars
Goodwill
22,859,000 US dollars
Operating lease right-of-use assets
21,773,000 US dollars
Other assets
5,025,000 US dollars
Property and equipment, net
4,834,000 US dollars
Current portion of long-term debt
63,783,000 US dollars
Accrued trade discounts and rebates
46,858,000 US dollars
Other accrued liabilities
39,706,000 US dollars
Accrued returns reserve
18,598,000 US dollars
Accounts payable
9,337,000 US dollars
Current operating lease liabilities
6,310,000 US dollars
Other current liabilities
4,976,000 US dollars
Debt, net of unamortized debt issuance costs, non-current portion
188,807,000 US dollars
Non-current operating lease liabilities
30,542,000 US dollars
Other liabilities
12,722,000 US dollars
Additional paid in capital
690,432,000 US dollars
Common stock—par value $0.0001, 350,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 173,591,637 and 166,215,410 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
18,000 US dollars
Preferred stock—par value $0.0001, 25,000,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025
0 US dollars
Accumulated deficit
negative 700,174,000 US dollars
Accumulated other comprehensive loss
negative 10,000 US dollars

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
XERIS BIOPHARMA HOLDINGS, INC. (XERS) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!